Key result
Cardioselective β-blockers like bisoprolol benefit hypertension, IHD, and HF primarily through β1 receptor blockade.
Why the study?
Aspects of the benefit/risk balance of beta-blockers remain controversial, and recent meta-analyses have shed new light on this issue.
Cardioselective β1-blockers, such as bisoprolol, are preferred over those with intrinsic sympathomimetic activity for improving clinical outcomes in hypertension, ischemic heart disease, and heart failure.
Answers are grounded in this paper and cite their sources.
May favor cardioselective β1-blockers like bisoprolol in hypertension, ischemic heart disease, and heart failure; leaves open prospective confirmation.
β-blockers are a heterogeneous class of drugs, with varying selectivity/specificity for β1 vs β2 receptors, intrinsic sympathomimetic activity (ISA), and vasodilatory properties (through β2 stimulation, α receptor blockade or nitric oxide release). These drugs are indicated for the management of arterial hypertension, heart failure or ischemic heart disease (IHD; eg angina pectoris or prior myocardial infarction). Most of the benefit of β-blockade in these conditions arises from blockade of the β1 receptor, and, in practice, the addition of ISA appears to reduce the potential for improved clinical outcomes in people with heart failure or IHD. Aspects of the benefit/risk balance of β-blockers remain controversial, and recent meta-analyses have shed new light on this issue. We have reviewed the current place of cardioselective β-blockade in hypertension, IHD and heart failure, with special reference to the therapeutic profile of a highly selective β1-adrenoceptor blocker, bisoprolol.
No takes yet. Share an insight, caveat, or question.
Pathak et al. (2021) conducted a review in Hypertension, Ischemic Heart Disease, Heart Failure. Cardioselective β-blockers (bisoprolol) was evaluated. Cardioselective β-blockers, particularly bisoprolol, provide clinical benefits in hypertension, ischemic heart disease, and heart failure primarily through β1 receptor blockade.
Synapse has enriched 10 related papers. Consider them for comparative context: